VC
GRCL

Vivo Capital’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Vivo Capital’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-9,546,485
Closed -$95.8M – 49
2023
Q4 		$95.8M Sell
9,546,485
-1,334,659
-12% -$6.06M 7.85% 2
2023
Q3 		$31.3M Buy
10,881,144
+6,911,717
+174% +$25.3M 3.43% 10
2023
Q2 		$15.1M Buy
3,969,427
+2,505,444
+171% +$7.02M 1.04% 14
2023
Q1 		$2.72M Buy
1,463,983
+502,625
+52% +$1.05M 0.19% 39
2022
Q4 		$2.21M Sell
961,358
-1
-0% -$3 0.25% 41
2022
Q3 		$3.1M Hold
961,359
– – 0.34% 43
2022
Q2 		$5.29M Hold
961,359
– – 0.53% 36
2022
Q1 		$2.24M Hold
961,359
– – 0.15% 49
2021
Q4 		$5.81M Hold
961,359
– – 0.35% 44
2021
Q3 		$13.3M Sell
961,359
-366,898
-28% -$4.33M 0.6% 31
2021
Q2 		$17.3M Sell
1,328,257
-194,737
-13% -$2.61M 0.75% 28
2021
Q1 		$23.5M Buy
+1,522,994
New +$35.9M 0.82% 26

Vivo Capital's GRCL Position: Q1 2024 in Review

Vivo Capital sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 9,546,485 shares — an estimated $95.8M sold.

Vivo Capital first reported a position in GRCL in Q1 2021 and held it in 12 quarters. The position peaked at $95.8M in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

  • Vivo Capital reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
  • Vivo Capital sold 9,546,485 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $95.8M.
  • Vivo Capital first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 12 quarters.
  • Vivo Capital's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $95.8M in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Vivo Capital's 13F filing for Q1 2024, filed 22 Apr 2024.